\textbf{Staphylococcus aureus Infections: New Challenges from an Old Pathogen}

Zeina A. Kanafani and Vance G. Fowler Jr.
Division of Infectious Diseases, Duke University Medical Center, Durham, NC.

\textit{Introduction}

Despite major advances in the medical arena, \textit{Staphylococcus aureus} remains an important agent of infectious diseases in the human host. Its significance lies in its widespread existence and the broad spectrum of infections it can produce, ranging from inconsequential superficial skin infections to deep-seated life-threatening systemic infections\(^1\). Indeed, some infections caused by \textit{S. aureus}, namely bacteremia and endocarditis, are frequently associated with serious complications and high mortality rates\(^2-4\). The emergence of antibiotic resistance has brought renewed attention to \textit{staphylococci}\(^5\). Methicillin-resistant \textit{S. aureus} (MRSA) rates both in hospitalized and ambulatory patients have been escalating, and this resistant phenotype is now considered a major public health problem\(^6,7\). Reduced susceptibility to other antimicrobials, including glycopeptides, is being increasingly rec-
ognized and further complicates the treatment of staphyloccocal infections9,12. In this review, the authors report on the current trends in the epidemiology, diagnosis, clinical syndromes, and management of S. aureus infections in light of the organism’s evolving antimicrobial resistance pattern.

Microbiology

Staphylococcus aureus belongs to the Micrococaceae family. It is a nonmotile, non-spore forming, gram-positive coccus that may occur singly, or in pairs, short chains, or grape-like clusters. It is a facultative anaerobe, but grows better under aerobic than anaerobic conditions. The organism produces catalase and coagulase and grows readily on blood and chocolate agar. Colonies measure 1 to 3 mm and typically produce a yellow to golden pigment due to the presence of carotenoids. Most strains produce hemolysis within 24 to 36 hours on horse, sheep, or human blood agar plates13.

Epidemiology

Worldwide epidemics of S. aureus disease have been recognized over the years13,14. Outbreaks have been reported in a variety of settings, including hospitals15, long-term care facilities16 and outpatient clinics17, as well as in the community18.

Nosocomial Infections

Staphylococci have been long recognized as a problem on hospital wards, and the policy of routine ongoing surveillance for hospital-acquired staphylococcal disease is well justified19-25. S. aureus is the leading cause of postoperative wound infection, and the second most frequent cause of nosocomial pneumonia26,27 and bacteremia28. Together, S. aureus and coagulase-negative staphylococci account for 21% of the estimated 4 million infections acquired annually in United States hospitals29. S. aureus nosocomial infections entail great expenditure. Over a two-year period from 2000 to 2001, the average cost of hospitalization in 994 US hospitals for patients with S. aureus infections was $48,654 compared to $14,414 for patients without such infections29. In another study, the mean infection-related costs in patients with prosthetic devices and S. aureus bacteremia (SAB) amounted to $67,439 for hospital-acquired infections and $87,368 for community-acquired infections30. In addition to the substantial economic burden, significant morbidity and mortality are associated with staphylococcal infections, particularly with invasive infections where mortality rates range between 19% and 34%29,32,33.

Community-acquired infections

Staphylococcus aureus infections are commonly acquired outside the hospital, particularly among colonized individuals, and have been reported for several decades33-38. However, the prevalence of infections caused by MRSA isolates has increased significantly. A Texas-based study in children noted a 14-fold increase in the rate of community-acquired MRSA infections in 2002 compared to previous years33. Similarly among adults, the incidence of community-acquired staphylococcal infections varied from 29% in 1997 to 74% in 200221. In addition, recent studies have demonstrated a substantial increase in the rate of nasal colonization with MRSA in the community, from 0.8% in 2001 to 9.2% in 200431.

Nasal carriage

Staphylococcus aureus may be carried by normal people at various body sites without causing disease. This condition is referred to as colonization to distinguish it from actual infection. It should be noted, however, that colonization frequently precedes infection in susceptible patients34. The anterior nares are the principal sites of colonization with three distinct patterns in the population: persistent carriers (20%), intermittent carriers (60%), or noncarriers (20%)35. Whereas 10%-30% of healthy adults are persistently colonized with S. aureus, populations with higher colonization rates include patients with atopic dermatitis (up to 85%)36, as well as surgical patients37, hemodialysis patients38, HIV-infected patients39, and those with intravascular devices40. Health care workers who come in contact with patients colonized or infected with S. aureus have higher rates of nasal carriage than providers without such contact41,42, and they may develop clinical disease following colonization43. In turn, colonized health care workers can serve as vehicles for the transmission of S. aureus to patients. In fact, nosocomial outbreaks are frequently attributed to colonization of the nares and hands of health care workers44,45.

Antimicrobial Resistance Trends

The propensity of S. aureus to develop resistance to virtually all the antimicrobial agents available to date has had a monumental impact on clinical infectious diseases. The present day epidemiology of staphylococcal infections has been shaped to a great extent by the rising antibiotic resistance rates commensurate with selective antibiotic pressure.

Resistance to beta-lactams

The first report of penicillinase-producing S. aureus was published in 1940, almost a year before penicillin was marketed for clinical use46. Since then, beta-lactamase mediated penicillin resistance has been widely described among S. aureus isolates, with 80%-93% resistance rates currently reported in the hospital and the community47,48. Penicillinase-stable cephalosporins and semisynthetic penicillins were introduced in the late 1950s. Once again, S. aureus was quick to develop resistance and MRSA isolates were described shortly thereafter49. Methicillin resistance has been steadily increasing. According to data from the National Nosocomial Infections Surveillance (NNIS) System, the prevalence of MRSA among hospitalized patients rose from 31.9% in 1996 to 60.7% in 2004 (fig. 1)50,51. Similar trends have been observed worldwide, although actual MRSA prevalence is subject to wide geographical variation. For instance, in Europe, MRSA rates as high as 58.0% in Italy and 54.0% in Portugal have been recently reported50. In Japan, nearly 70% of S. aureus bloodstream isolates in 2001 were methicillin-resistant52. On the other hand, Scandinavian countries have consistently noted very low rates of MRSA53. Several risk factors have been independen-
Temporal trends of MRSA rates according to data from the NNIS System. MRSA: methicillin-resistant St. aureus; NNIS: National Nosocomial Infection Surveillance; ICU: intensive care unit.

Although initially confined to the hospital setting, MRSA isolates are now increasingly encountered in the community. Over the past decade, community-acquired MRSA (CA-MRSA) has quickly become a public health problem of epidemic proportions (CA-MRSA) has quickly become a public health problem of epidemic proportions. NNIS data suggest that in 2004, 50.5% of S. aureus isolated from outpatients were methicillin-resistant (fig. 1). In addition, a recent meta-analysis reported a 30.2% rate of community-onset MRSA infections from 27 studies. These figures, however, include outpatients with healthcare-associated infections. When applying strict definitions and excluding patients with healthcare-associated risk factors, CA-MRSA rates vary from 18.0 to 25.7 cases per 100,000 population. Multiple outbreaks of invasive infections caused by CA-MRSA have been described. Susceptible populations include children in day care centers, athletic teams, Native American communities, military personnel, and prison inmates. Patients with CA-MRSA commonly present with suppurative skin infections or necrotizing pneumonia. The ability of the organism to produce such invasive infections has been associated with Panton-Valentine leukocidin (PVL), a hemolysin encoded by the pvl gene located on a mobile plasmid. The presence of pvl and other distinct bacterial genetic characteristics, including the presence of staphylococcal chromosomal cassette 4 (SCCmec 4), have been associated with severe cutaneous and pulmonary infections caused by community-acquired MRSA strains.

Recent reports document that the epidemiology of CA-MRSA is increasingly blurring with that of hospital-acquired MRSA. A recent report from Atlanta documented that USA300, the most common CA-MRSA clone in the United States, is also a frequent cause of nosocomial and healthcare-associated bacteremia. The effect of methicillin resistance on patient outcome has been a matter of intense debate. A number of studies addressing this issue have noted conflicting results in the setting of various S. aureus infections and various patient populations. Whether the deleterious effect of MRSA observed in some of these studies is due to inherent virulence of the resistant strains or rather related to failure of vancomycin therapy remains unsettled. The advent of new antimicrobial agents with superior bactericidal activity compared to vancomycin will provide better chances in the future to accurately identify methicillin resistance through careful adjustment for the comorbid conditions of individual patients.

Resistance to glycopeptides

Staphylococcus aureus isolates with intermediate and high-level resistance to glycopeptides have been described. Different mechanisms account for the two types of resistance. Vancomycin-intermediate S. aureus (VISA) harbors mutations that result in thickening of the peptidoglycan layer. Such resistance might be overcome with high doses of vancomycin. Conversely, vancomycin-resistant S. aureus (VRSA) have acquired the VanA resistance gene from enterococcal species and therefore do not exhibit a dose-dependent resistance to vancomycin. Although vancomycin resistance rates are still low, the emergence of such strains might be inevitable, especially with the continued pressure posed by intense glycopeptide use.

**Figure 1** Temporal trends of MRSA rates according to data from the NNIS System. MRSA: methicillin-resistant S. aureus; NNIS: National Nosocomial Infection Surveillance; ICU: intensive care unit.

**Diagnosis**

Sites of staphylococcal infection are usually teeming with organisms. S. aureus grows on ordinary laboratory media and can be readily recognized on Gram stains from most clinical specimens. Definitive identification then relies on the tube or slide coagulase test, followed by antibiotic susceptibility testing through disk diffusion or tube-dilution techniques. This method for MRSA identification relies on growing the organism in culture and then performing susceptibility testing; therefore it has a turnaround time of 48-72 hours. Recently developed polymerase chain reaction (PCR) assays provide a more rapid means for identifying MRSA isolates, and are especially valuable in detecting nasal colonization and bloodstream infections. Similar assays can now detect the pvl gene in clinical S. aureus isolates.

During outbreaks, phage typing of staphylococci is useful for recognizing the epidemic strain. More recently, molecular typing methods have provided reliable results. These include restriction endonuclease analysis of plasmid DNA, pulsed-field gel electrophoresis of DNA, and polymerase chain reaction amplification of selected DNA sequences.

The serological diagnosis of S. aureus bacteremia has been evaluated. Antibodies to a variety of staphylococcal antigens have been tested including peptidoglycan, teichoic acid, S. aureus lysate, whole S. aureus cell wall, alpha-toxin, lipase and capsular polysaccharide. Whole cell ELISA has been shown to be the most sensitive assay although all tests lacked specificity. Studies suggest that the presence of antibodies to S. aureus teichoic acid might indicate a chronic deep seated infection, including endocarditis, chronic osteomyelitis, and septic arthritis, whereas patients with uncomplicated bacteremia, acute os-
TABLE 1. Selection of studies comparing outcomes of patients with S. aureus infections with respect to methicillin resistance

<table>
<thead>
<tr>
<th>Author (reference)</th>
<th>Setting</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austin et al115</td>
<td>Bacteremia</td>
<td>Trend towards increased attributable mortality with MRSA</td>
</tr>
<tr>
<td>Blot et al116</td>
<td>Bacteremia in critically ill patients</td>
<td>Higher attributable mortality with MRSA</td>
</tr>
<tr>
<td>Chang et al117</td>
<td>Community-acquired bacteremia</td>
<td>Higher mortality, increased risk of persistent bacteremia and renal insufficiency with MRSA</td>
</tr>
<tr>
<td>Combes et al118</td>
<td>Post-sternotomy mediastinitis</td>
<td>No difference in duration of mechanical ventilation or ICU mortality</td>
</tr>
<tr>
<td>Congrove et al119</td>
<td>Bloodstream infections</td>
<td>Longer hospital stay and higher hospital charges with MRSA</td>
</tr>
<tr>
<td>Concie et al120</td>
<td>Nosocomial infections</td>
<td>Increased hospital stay with MRSA, no effect on mortality</td>
</tr>
<tr>
<td>Engemann et al121</td>
<td>Surgical site infections</td>
<td>Increased mortality and hospital charges with MRSA</td>
</tr>
<tr>
<td>Harborth et al122</td>
<td>Bacteremia</td>
<td>No effect on in-hospital mortality</td>
</tr>
<tr>
<td>Hershow et al123</td>
<td>Nosocomial infections</td>
<td>No effect on outcome</td>
</tr>
<tr>
<td>Kopp et al124</td>
<td>Various infections</td>
<td>Worse clinical and economic outcomes with MRSA</td>
</tr>
<tr>
<td>Lodise et al125</td>
<td>Bacteremia</td>
<td>Increased length of stay and higher costs of hospitalization with MRSA</td>
</tr>
<tr>
<td>Martinez-Aguilar et al126</td>
<td>Musculoskeletal infections in children</td>
<td>Greater febrile days and hospital days with MRSA, no effect on final outcome</td>
</tr>
<tr>
<td>Marty et al127</td>
<td>Bacteremia in cancer patients</td>
<td>No effect on outcome</td>
</tr>
<tr>
<td>Mekontso-Dessap et al128</td>
<td>Post-sternotomy mediastinitis</td>
<td>Worsen clinical outcome and higher overall mortality with MRSA</td>
</tr>
<tr>
<td>Melnor et al129</td>
<td>Nosocomial bacteremia</td>
<td>Trend towards increased mortality with MRSA, no effect on risk of dissemination</td>
</tr>
<tr>
<td>Reed et al130</td>
<td>Bacteremia in HD patients</td>
<td>Higher mortality, longer hospital stay, higher inpatient costs with MRSA</td>
</tr>
<tr>
<td>Romero-Vivas et al131</td>
<td>Nosocomial bacteremia</td>
<td>Higher mortality with MRSA</td>
</tr>
<tr>
<td>Selvey et al132</td>
<td>Nosocomial bacteremia</td>
<td>No difference in mortality</td>
</tr>
<tr>
<td>Whitby et al133</td>
<td>Bacteremia (meta-analysis)</td>
<td>Increased mortality with MRSA</td>
</tr>
<tr>
<td>Yoon et al134</td>
<td>Infective endocarditis</td>
<td>Higher risk of persistent bacteremia and trend towards higher mortality with MRSA</td>
</tr>
<tr>
<td>Zahar et al135</td>
<td>Ventilator-associated pneumonia</td>
<td>No effect on ICU or hospital mortality</td>
</tr>
</tbody>
</table>

MRSA: methicillin-resistant S. aureus; HD: hemodialysis; ICU: intensive care unit.
Infective endocarditis (IE) complicates the course of SAB in ~12% of cases. In a recent large cohort of patients, *S. aureus* was the most common cause of native valve endocarditis. Recent years have witnessed a rise in the rates of IE due to *S. aureus*. *S. aureus* is now the leading cause of IE in many parts of the world. This trend is mostly attributed to the increasing prevalence of healthcare-associated *S. aureus* IE that has accompanied the growing use of interventional procedures, intravascular catheters, and implantable devices. For instance, Fernandez-Guerrer et al reported a 10-fold increase in the number of cases of hospital-acquired IE (most of which were due to *S. aureus*) from 1976 to 1992 compared to the number of cases occurring from 1960 to 1975. The increasing frequency of *S. aureus* IE can also be ascribed to better recognition of the disease through the widespread application of echocardiography in evaluating patients with SAB. Endocarditis in patients with SAB frequently involves normal cardiac valves and is seldom accompanied by the physical stigmata of IE, rendering the diagnosis of the disease difficult. In fact, relapse solely upon physical examination findings is likely to result in underdiagnosis of *S. aureus* IE in a large number of cases. Because of the difficulty in clinically identifying *S. aureus* IE, the use of echocardiography has been advocated to evaluate patients with SAB. Despite its limited sensitivity in detecting vegetations (64%), transesophageal echocardiography (TEE) is a widely available, non-invasive screening modality in the setting of SAB. Conversely, transesophageal echocardiography (TEE) offers significant advantages over TTE, including higher sensitivity in identifying IE (80% vs. 14%), improved identification of IE complications, and an enhanced ability to exclude IE in patients with native valves (negative predictive value 100%) (154). Whether TTE or TEE should be employed in the initial screening of the patient presenting with SAB remains a controversial issue. TEE is currently highly favored at our institution for the evaluation of most patients with SAB. The authors believe that TEE is likely to be cost-effective to guide duration of therapy in patients with intravascular catheter-associated SAB or for patients at higher risk for IE or associated complications.

Despite early diagnosis and appropriate therapy, IE following SAB is often associated with devastating and life-threatening sequelae. The overall mortality of *S. aureus* IE ranges from 19% to 30% (5,134,135). Other complications include heart failure (20%-50%), 

Pneumonia

*Staphylococcus aureus* is a significant etiologic agent in lower respiratory tract infections that has become increasingly more common in the hospital setting. According to the NNIS System, *S. aureus* was responsible for 20% of nosocomial pneumonias between 1992 and 1997. Furthermore, in the European Prevalence of Infection in Intensive Care (EPIC) Study, *S. aureus* was the predominant infective agent, accounting for 31% of microbiologically proven cases of ventilator-associated pneumonia. Whereas methicillin-susceptible *S. aureus* (MSSA) is typically encountered in early-onset hospital acquired pneumonia (<5 days after admission), MRSA gains importance in late-onset hospital-acquired pneumonia and particularly in ventilator-associated pneumonia. Nosocomial pneumonia due to MRSA entails significant mortality with rates ranging from 38% to 55% (136). As with other *S. aureus* infections, whether methicillin resistance by itself contributes to the poor outcome is still a matter of debate (136). In addition to its role as a nosocomially acquired pulmonary pathogen, *S. aureus* has recently established itself as an emergent threat in the community. Necrotizing pneumonia and sepsis caused by community-acquired MRSA strains carrying pvl genes are being increasingly recognized (137-139). Afflicted patients are typically healthy individuals without any healthcare contact. These infections are characterized by multifocal involvement of various organs, including lungs, brain, heart, liver, and kidneys. The pathological feature in the lungs is extensive hemorrhagic necrosis of the pulmonary parenchyma (137-139). The mean case fatality rate is noted to be as high as 35% (137,138,140,141). Mortality seems to be tightly linked to the presence of the pvl gene; in a study of *S. aureus* pneumonia, the mortality rate was 92% in cases with pvl-positive strains, as compared to 6% in those with pvl-negative strains (137). *Staphylococcus aureus* pneumonia can present in several different forms, often in parallel with distinct pathophysiological mechanisms: 1) Lobar pneumonia usually occurs as a result of aspiration. Patients are acutely ill with high fevers and productive cough. In severe infections, empyema, abscess formation, cavitary and pneumatoceles may be present. 2) Ventilator-associated pneumonia usually follows microaspiration and often develops in conjunction with, or following viral pneumonia. 3) Peripheral localized areas of pneumonia are noted with hematogenous seeding of the lungs from septic
emboli secondary either to right-sided endocarditis or to soft tissue or joint infection. In this type of S. aureus pneumonia, pleuritic chest pain is a hallmark feature whereas cough and sputum production are less likely.214-216

**Novel therapies for MRSA**

The use of beta-lactams in the treatment of S. aureus infections has been greatly handicapped by the increasing prevalence of MRSA strains. Although vancomycin, the traditional alternative antimicrobial agent, still maintains in-vitro activity against the majority of MRSA isolates, clinical cure rates in serious infections are disheartening. Treatment failure rates exceeding 40% have been recently quoted for SAB185 and S. aureus pneumonia186 treated with vancomycin. This has kindled great interest in developing new treatment options for MRSA.

**Quinupristin/dalfopristin**

Quinupristin and dalfopristin belong to the streptogramin class of antibiotics. When combined, these two agents are bactericidal and act in synergy on the 50S ribosomal subunit to inhibit protein synthesis. Quinupristin/dalfopristin is active in-vitro against both MSSA and MRSA187. The drug is approved by the Food and Drug Administration (FDA) only for the treatment of complicated skin and skin structure infections (cSSSI) due to MSSA188. However, data from a small controlled trial have suggested that quinupristin/dalfopristin is equivalent to vancomycin in the treatment of catheter-related bacteremia caused by S. aureus or coagulase-negative staphylococci (50% clinical and bacteriological responses in both groups)189. Another study compared in a randomized design quinupristin/dalfopristin to vancomycin in the treatment of nosocomial pneumonia. Although both drugs were comparable in clinical efficacy (56% vs. 58%, respectively), the number of episodes of pneumonia caused by S. aureus was relatively small in both arms190. Quinupristin/dalfopristin has also shown promising results in experimental rat and rabbit models of S. aureus endocarditis along191 or in combination with various antimicrobial agents such as beta-lactams186, aminoglycosides101, rifampin192, and vancomycin193. Limited Compassionate Use Registry data are available regarding the use of quinupristin/dalfopristin as a treatment option in patients with serious MRSA infections who are failing or are intolerant of traditional therapy194. However, the cost, the requirement for administration by central catheter, and the side effect profile have all limited the use of this agent195-198.

**Linezolid**

Linezolid is an oxazolidinone antimicrobial agent that binds reversibly to the bacterial 23S ribosome, thereby inhibiting protein synthesis. As a result of reversible inhibition, linezolid exhibits bacteriostatic activity against S. aureus. A major advantage offered by this new drug is an oral bioavailability of approximately 100%.207 Linezolid is indicated for the treatment of MRSA in the setting of cSSSI including diabetic foot infections without osteomyelitis. It has similar clinical efficacy as vancomycin in such infections but was statistically superior to vancomycin with regard to bacterial eradication in patients with confirmed MRSA at baseline207. More recently, linezolid obtained FDA approval for the treatment of nosocomial pneumonia215-217. According to a recent pooled analysis of randomized studies, linezolid was not inferior to vancomycin in the treatment of SAB (55% vs. 52%, respectively for overall cure rate)218. The use of linezolid in MRSA endocarditis has had conflicting results. Although some reports described successful outcomes219-221, there have been recent cases of clinical failure (one of which was fatal) with linezolid despite favorable in-vitro susceptibility results222,223. Consequently, the authors do not recommend the use of linezolid in the setting of MRSA endocarditis regardless of the antimicrobial susceptibility of the isolate.

**Daptomycin**

Daptomycin is a cyclic lipopeptide with rapid bactericidal activity against MRSA. It exerts its action by inserting itself into the bacterial cell membrane. Subsequent events that lead to bacterial cell killing are not fully understood but are thought to involve dissipation of membrane potential. Daptomycin is FDA-approved for the treatment of cSSSI due to S. aureus including MRSA. In two distinct Phase III trials in patients with cSSSI, daptomycin resulted in similar success rates as its comparator—semi-synthetic penicillin or vancomycin (71.5% and 71.1%, respectively)196. Despite lacking a formal indication, daptomycin was used considerably in the setting of SAB and S. aureus endocarditis219-221. Currently, phase III trials are being conducted to evaluate the efficacy of daptomycin in staphylococcal bloodstream infections. Daptomycin is not indicated in the treatment of pneumonia: the drug is inhibited by pulmonary surfactant222 and proved to be inferior to ceftaroline in a Phase III trial223.

**Tigecycline**

Tigecycline is a newly introduced glycycline derivative with structural homology to tetracyclines. This drug offers broad-spectrum antimicrobial coverage including MRSA through binding to the 30S ribosomal subunit. Tigecycline has received FDA approval for the treatment of complicated intrabdominal infections224. In addition, animal models have shown promising results with tigecycline compared to vancomycin in MRSA endocarditis225.

**Dalbavancin**

Dalbavancin is a semisynthetic glycopeptide characterized by a long half-life (9-12 days) that allows once-weekly administration. It exerts its potent activity against MRSA via inhibition of cell wall synthesis. Dalbavancin has shown positive results in Phase III studies in cSSSI226 and in a Phase II study in catheter-related bloodstream infections227. It is currently awaiting FDA approval for these indications.

**Telavancin**

Telavancin is an experimental lipoglycopeptide molecule characterized by two mechanisms of action: inhibition of bacterial peptidoglycan synthesis; and alteration of bacterial cell membrane permeability and depolarization. Telavancin exhibits bactericidal in-vitro activity against S. aureus isolates including MSSA, MRSA and VISA isolates. In animal infection models, telavancin was efficacious in the treatment of various MRSA infections including soft tissue infections228, pneumonia229, and endocarditis230. In Phase II clinical trials, telavancin was compared to stan-
dard therapy (semisynthetic penicillin or vancomycin) in patients with cSSSI. Data from this study showed that telavancin was equivalent to standard therapy both in clinical cure in the all treated population (79% vs. 80%) as well as in microbiological eradication in the MRSA subgroup (87.8% vs. 80.0%, P = 0.43). Phase III trials designed to de-

monstrate superiority over vancomycin are currently un-
derway in patients with cSSSI, uncomplicated bacteremia, and hospital-acquired pneumonia.

Immunotherapy

Since microbial adherence is central to the initiation and metastatic spread of S. aureus, the MSCRAMM (microbial surface components recognizing adhesive matrix molecules) family of bacterial surface adhesion proteins represents an excellent target for the development of novel immunothera-
pies. Tefibazumab is a humanized IgG monoclonal antibody with high affinity to clumping factor A, an MSCRAMM pro-

tein common to virtually all S. aureus strains. It interferes with S. aureus adherence to extracellular matrix proteins in vitro and may enhance opsonophagocytosis of S. aureus by polymorphonuclear leukocytes. In an animal model of S. aureus IE, addition of tefibazumab to vancomycin significa-
tically increased bacterial clearance from the bloodstream when compared to vancomycin alone (P < 0.008). The re-

sults of a Phase II randomized, double-blind, multi-center clinical study of tefibazumab in patients with SAB were re-
cently presented.

Prevention

Nasal decolonization

Since MRSA nasal colonization frequently precedes in-
fection, endeavors to contain the transmission of MRSA have targeted the eradication of nasal carriage in suscep-
tible patients. Studies evaluating this strategy have yield-
ed conflicting results. Cardiac surgery patients who received mupirocin prophylaxis had a lower surgical infection rate than historical controls (7.3% vs. 2.8%, P < 0.011). More recently, combining results from two randomized trials in surgical patients suggested that the administration of mupirocin in surgical patients re-
duced postoperative nosocomial S. aureus infections as compared to placebo (RR 0.49, 95% CI 0.28-0.85; number needed to treat 26-100). Bookert et al found a four- to six-fold reduction in SAB rates in hemodialysis patients receiving mupirocin. On the other hand, one study in nonsurgical patients failed to show a benefit from mupirocin prophylaxis with respect to rates of nosocomial S. aureus infections, in-hospital mortality, and duration of hospitalization. Investigators have therefore suggested that a single course of mupirocin may be insufficient in low-risk patients with prolonged exposure.

In addition to conflicting messages from clinical trials, the emergence of mupirocin-resistance has also been reported.

Vaccination

Staphylococcus aureus Poly saccharide Conjugate Vaccine (StaphVax®, Nabi Biopharmaceuticals, Rockville, MD) is an investigational polysaccharide conjugate vaccine that presents a novel approach to the prevention of S. aureus in-
fections. It consists of type 5 and type 8 capsular polysaccharides, the strains accounting for more than 80% of infec-
tions. In one double blinded, placebo-controlled Phase III clinical efficacy trial involving 1804 hemodialysis-dependent patients, StaphVax recipients failed to meet the a priori endpoint of reduction in episodes of S. aureus bacteremia at 54 weeks. However, post hoc analysis revealed a 57% re-
duction in SAB episodes at 10 months compared to placebo recipients (P = 0.015). Based on these findings, a second Phase III confirmatory trial, with modified time points, was undertaken. However, this second trial also failed to meet its primary endpoint. As a result, all clinical trial develop-
ment and further marketing of StaphVax have been held until assessment of the results is completed.

Infection control strategies

Several studies have established that the transmission of MRSA between patients within the hospital setting occurs to a great extent through health care workers. Consequently, the Centers for Disease Control and Prevention (CDC) recommend the implementation of contact precau-
tions in patients colonized or infected with MRSA. Such precautions include the use of private rooms, protecti-
ve attire for health care workers, and strict adherence to hand hygiene principles. There is abundant evidence to support the efficacy of these infection control programs in reducing the transmission of resistant pathogens within the hospital. Although active surveillance for MRSA and preemptive isolation of colonized or infected patients remains an integral part of many hospital infection control programs, observance of infection control guidelines has been suboptimal. Hand hygiene practices have been particularly inadequate. Accordingly, continuous ef-
efforts should be made to improve compliance with isolation and hand hygiene policies to prevent the dire consequences of nosocomial MRSA transmission.

References

4. Petit CA, Petti CA, Jr. Staphylococcus aureus bacteremia and endocardi-
6. Collie DP, Durbin LJ, Germann TP, Trunen DM, Smith RB, Fourn RM. Spread of methicillin-resistant Staphylococcus aureus (MRSA) among hou-
9. Moghli A, Rice L, Stupica DR, Horner DM. Daptomycin-resistant, methi-
11. Travers FC, McDaid LC. Vancomycin-resistant staphylococci and epi-


Staphylococcus aureus infections: New Challenges from an Old Pathogen

Karen KA and Forster VI. Staphylococcus aureus Infections: New Challenges from an Old Pathogen


Infections: New Challenges from an Old Pathogen
infections in haemodialysis patients.
or vancomycin-intermediate.
Kanafani ZA and Fowler Jr VG.
Dresser LR, Doig C, Maki DG, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of mupirocin nasal ointment in a double-blind, randomi-
Kanafani ZA, Maki DG, Tally FP, Campanaro E, Eisenstein BI. The safety and ef-
Cromer AL, Hotston-Russell SJ, Lathiam SC, García-Vidalobos J, Garcia JL, So-